EUVIMEDEUVIMED entdecken
Crossref

Acquired amegakaryocytic thrombocytopenia: a diagnostic pitfall in refractory thrombocytopenia

Serkan Güven

Journal of Current Hematology & Oncology Research · 13.11.2026 · 4 (4) · 166-167

DOI: 10.51271/jchor-0102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 13.11.2026. Verfasst von Serkan Güven.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired amegakaryocytic thrombocytopenia (AAT) is a rare hematologic disorder characterized by severe isolated thrombocytopenia caused by a selective reduction or complete absence of bone marrow megakaryocytes while other hematopoietic lineages remain relatively preserved. Because its initial clinical presentation frequently overlaps with immune thrombocytopenia (ITP), delayed diagnosis and prolonged exposure to ineffective ITP-directed therapies are common in clinical practice.

Zitieren

APA

Güven, S. (2026). Acquired amegakaryocytic thrombocytopenia: a diagnostic pitfall in refractory thrombocytopenia. Journal of Current Hematology & Oncology Research, 4(4), 166-167. https://doi.org/10.51271/jchor-0102

Vancouver

Güven S. Acquired amegakaryocytic thrombocytopenia: a diagnostic pitfall in refractory thrombocytopenia. Journal of Current Hematology & Oncology Research. 2026;4(4):166-167. doi:10.51271/jchor-0102

BibTeX
@article{Gven2026,
  author = {Güven, Serkan},
  title = {Acquired amegakaryocytic thrombocytopenia: a diagnostic pitfall in refractory thrombocytopenia},
  journal = {Journal of Current Hematology & Oncology Research},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {166--167},
  doi = {10.51271/jchor-0102}
}
Kostenlos starten →